国际口腔医学杂志 ›› 2021, Vol. 48 ›› Issue (1): 50-57.doi: 10.7518/gjkq.2021013

• 论著 • 上一篇    下一篇

脂多糖结合蛋白在口腔鳞状细胞癌中的表达及其临床意义

黄俊文1,乔洁2,梅子1,陈茁1,李杨1,乔彬1()   

  1. 1. 郑州大学第一附属医院口腔颌面外科 郑州 450052
    2. 湖北大学生命科学学院 省部共建生物催化与酶工程国家重点实验室 武汉 430062
  • 收稿日期:2020-05-26 修回日期:2020-09-16 出版日期:2021-01-01 发布日期:2021-01-20
  • 通讯作者: 乔彬
  • 作者简介:黄俊文,硕士,Email: bettermore1993@163.com
  • 基金资助:
    河南省科技厅项目(182300410319)

Expression and clinical significance of lipopolysaccharide binding protein in oral squamous cell carcinoma

Huang Junwen1,Qiao Jie2,Mei Zi1,Chen Zhuo1,Li Yang1,Qiao Bin1()   

  1. 1. Dept. of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
    2. State Key Laboratory of Biocatalysis and Enzyme Engineering, School of Life Sciences, Hubei University, Wuhan 430062, China
  • Received:2020-05-26 Revised:2020-09-16 Online:2021-01-01 Published:2021-01-20
  • Contact: Bin Qiao
  • Supported by:
    This study was supported by Project of Department of Science and Technology of Henan Province(182300410319)

摘要:

目的 探讨脂多糖结合蛋白(LBP)在口腔鳞状细胞癌(OSCC)中的表达及其临床意义。方法 通过免疫组织化学实验分别检测LBP在48例OSCC患者的癌组织及其癌旁组织的表达情况,酶联免疫吸附试验分别检测130名OSCC患者和90名正常人血清中的LBP质量浓度,分析LBP与OSCC的临床病理特点的关系,并绘制受试者工作特征(ROC)曲线分析血清中LBP质量浓度在OSCC诊断中的价值。结果 与癌旁组织相比,LBP在OSCC组织中高表达(P<0.001),并且LBP与OSCC的肿瘤分期、淋巴结转移及临床分期有关,未发现LBP与OSCC患者的性别、年龄及病理分级有关(P>0.1)。同时,通过免疫组织化学实验发现CD204在OSCC中有类似的结果。与正常人相比,OSCC患者血清中LBP质量浓度升高(P<0.001),并与OSCC的肿瘤分期和临床分期有关(P<0.001)。ROC曲线下面积为0.876(P<0.001),LBP血清质量浓度的最佳截断值为0.733 μg·mL -1,特异性93.3%,敏感性80.0%。 结论 LBP与OSCC的发生发展有关,可能是其潜在的肿瘤标志物,提示LBP在OSCC的诊断中具有潜在的临床价值。

关键词: 脂多糖结合蛋白, 口腔鳞状细胞癌, 免疫组织化学双染, 酶联免疫吸附试验, 受试者特征工作曲线

Abstract:

Objective To investigate the expression and clinical importance of lipopolysaccharide binding protein(LBP) in oral squamous cell carcinoma (OSCC). Methods LBP expression in 48 OSCC tissues and matched adjacent normal tissues and LBP serum levels in 130 patients with OSCC and 90 normal individuals were measured by immunohistochemistry staining assay and enzyme-linked immunosorbent assay, respectively. The relationship between LBP expression and the clinicopathologic characteristics of OSCC was analysed by statistical methods. The diagnostic value of LBP serum level in OSCC was explored via receiver operating characteristic (ROC) curve. Results LBP expression was significantly upregulated in OSCC tissues, whereas little was expressed in adjacent normal tissues (P<0.001). Furthermore, LBP expression was closely associated with T-classification, node lymph metastasis and clinical stage (P<0.01) but not with the pathological grading, sex and age of patients (P>0.1). Meanwhile, it was found that CD204 had the similar results in OSCC through immunohistochemistry staining assay. The LBP serum level in patients with OSCC abnormally increased compared with that in normal individuals (P<0.001). LBP serum concentration was highly correlated to T-classification and clinical stage (P<0.001). Area under the ROC was 0.876 (P<0.001), and the optional cut-off value was 0.733 μg·mL -1 with 93.3% specificity and 80.0% sensitivity. Conclusion LBP contributes to the tumourigenesis and development of OSCC and could become a promising biomarker that might provide a useful clinical value in the early diagnosis of OSCC.

Key words: lipopolysaccharide binding protein, oral squamous cell carcinoma, immunohistochemical double-stai-ning, enzyme linked immunosorbent assay, receiver operating characteristic curve

中图分类号: 

  • R782.2

表 1

LBP的表达与OSCC患者临床病理特点的关系"

患者参数 病例数 CD204 P LBP P
性别 1.000 0.45
28 4.95(3.63~6.4) 1.32±0.54
20 4.93±0.92 1.15(0.90~1.56)
年龄/岁 0.788 0.649
<60 24 5.07±1.27 1.29±0.42
≥60 24 4.90(3.85~6.38) 1.31±0.53
临床分期 0.001 0.007
12 3.80(3.53~4.00) 1.05(0.90~1.30)
24 5.28±1.29 1.25(0.85~1.59)
12 5.65±1.13 1.75(1.20~2.20)
肿瘤分期 0.021 0.007
T1 14 3.85(3.57~4.60) 1.20(0.90~1.30)
T2 26 5.34±1.25 1.30(0.95~1.60)
T3 8 5.45±1.37 2.05(1.23~2.28)
病理分级 0.107 0.755
高分化 8 4.30±0.82 1.28±0.49
中分化 40 5.20(3.93~6.33) 1.30±0.48
淋巴结转移 0.007 0.039
N0 42 4.50(3.80~5.55) 1.24±0.45
N1-3 6 6.10(6.00~7.00) 1.70±0.50
组织来源 <0.001 <0.001
OSCC组织 48 4.90(3.93~6.08) 1.25(0.93~1.60)
癌旁组织 48 0.30(0.03~0.48) 0.05(0~0.20)

图1

LBP和CD204在OSCC组织中过表达 A和B:OSCC癌旁组织中LBP和CD204免疫组织化学双染代表性图(A为× 200,B为× 400); C和D:OSCC组织中LBP和CD204免疫组织化学双染代表性图(C为× 200,D为× 400);E:LBP和CD204在OSCC与癌旁组织中表达的量化评分。"

图2

LBP和CD204在不同的肿瘤分期以及临床分期OSCC中的表达 A、B、C:不同肿瘤分期的OSCC组织LBP和CD204免疫组织化学双染代表性图(× 200); D、E、F:不同临床分期的OSCC组织LBP和CD204免疫组织化学双染代表性图(× 200);G:不同肿瘤分期的OSCC中LBP和CD204表达水平的量化评分图;H:不同临床分期的OSCC中LBP和CD204表达水平的量化评分图。"

图3

LBP和CD204在不同的病理分级以及淋巴结转移OSCC中的表达 A、B:不同淋巴结转移状态的OSCC组织LBP和CD204免疫组织化学双染代表性图(× 200);C、D:不同病理分级的OSCC组织LBP和CD204免疫组织化学双染代表性图(× 200);E:不同淋巴结转移状态的OSCC中LBP和CD204表达水平的量化评分图;F:不同病理分级的OSCC中LBP和CD204表达水平的量化评分图。"

表2

LBP血清浓度与OSCC患者临床病理特点的关系"

患者参数 病例数 LBP/(μg·mL-1 P
性别 0.848
80 1.57(1.26~2.22)
50 1.55(1.39~1.94)
年龄/岁 0.63
<60 56 1.57±0.50
≥60 74 1.76(1.35~2.15)
临床分期 <0.001
28 1.37±0.24
48 1.63±0.60
44 1.78±0.59
10 2.73(2.11~3.11)
肿瘤分期 <0.001
T1 36 1.35(1.25~1.55)
T2 68 1.63±0.57
T3 26 2.01(1.88~2.8)
病理分级 0.221
高分化 26 1.51(1.27~1.60)
中分化 96 1.74(1.31~2.07)
低分化 8 1.78(1.35~2.24)
淋巴结转移 0.176
N0 94 1.56(1.28~1.93)
N1-3 36 1.61(1.41~2.28)

图4

The increased serum level of LBP in OSCC patients"

"

[1] Bray F, Ferlay J, Soerjomataram I , et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424.
[2] Siegel RL, Miller KD, Jemal A . Cancer statistics, 2019[J]. CA A Cancer J Clin, 2019,69(1):7-34.
[3] Grivennikov SI, Greten FR, Karin M . Immunity, inflammation, and cancer[J]. Cell, 2010,140(6):883-899.
[4] Hanahan D, Weinberg RA . Hallmarks of cancer: the next generation[J]. Cell, 2011,144(5):646-674.
doi: 10.1016/j.cell.2011.02.013 pmid: 21376230
[5] Schumann RR, Leong SR, Flaggs GW , et al. Structure and function of lipopolysaccharide binding protein[J]. Science, 1990,249(4975):1429-1431.
[6] Zweigner J, Schumann RR, Weber JR . The role of lipopolysaccharide-binding protein in modulating the innate immune response[J]. Microbes Infect, 2006,8(3):946-952.
doi: 10.1016/j.micinf.2005.10.006 pmid: 16483818
[7] Tsukamoto H, Takeuchi S, Kubota K , et al. Lipopolysaccharide (LPS)-binding protein stimulates CD 14-dependent Toll-like receptor 4 internalization and LPS-induced TBK1-IKKϵ-IRF3 Axis activation[J]. J Biol Chem, 2018,293(26):10186-10201.
[8] Ryu JK, Kim SJ, Rah SH , et al. Reconstruction of LPS transfer cascade reveals structural determinants within LBP, CD14, and TLR4-MD2 for efficient LPS recognition and transfer[J]. Immunity, 2017,46(1):38-50.
[9] Kopp F, Kupsch S, Schromm AB . Lipopolysaccharide-binding protein is bound and internalized by host cells and colocalizes with LPS in the cytoplasm: implications for a role of LBP in intracellular LPS-signaling[J]. Biochim Biophys Acta, 2016,1863(4):660-672.
[10] Boylan KL, Andersen JD, Anderson LB , et al. Quantitative proteomic analysis by iTRAQ(R) for the iden-tification of candidate biomarkers in ovarian cancer serum[J]. Proteome Sci, 2010,8:31.
[11] Kovacs G, Peterfi L, Farkas N , et al. Expression of inflammatory lipopolysaccharide binding protein (LBP) predicts the progression of conventional renal cell carcinoma‒a short report[J]. Cell Oncol (Dordr), 2017,40(6):651-656.
[12] Peterfi L, Yusenko MV, Kovacs G . IL6 shapes an inflammatory microenvironment and triggers the development of unique types of cancer in end-stage kidney[J]. Anticancer Res, 2019,39(4):1869-1874.
[13] Wang N, Song XG, Liu LS , et al. Circulating exosomes contain protein biomarkers of metastatic non-small-cell lung cancer[J]. Cancer Sci, 2018,109(5):1701-1709.
[14] Kouketsu A, Sato I, Oikawa M , et al. Regulatory T cells and M2-polarized tumour-associated macropha-ges are associated with the oncogenesis and progression of oral squamous cell carcinoma[J]. Int J Oral Maxillofac Surg, 2019,48(10):1279-1288.
[15] Yamagata Y, Tomioka H, Sakamoto K , et al. CD163-positive macrophages within the tumor stroma are associated with lymphangiogenesis and lymph node metastasis in oral squamous cell carcinoma[J]. J O-ral Maxillofac Surg, 2017,75(10):2144-2153.
[16] ASMRHaque, Moriyama M, Kubota K, et al. CD206 + tumor-associated macrophages promote proliferation and invasion in oral squamous cell carcinoma via EGF production [J]. Sci Rep, 2019,9(1):14611.
[17] Wang B, Liu H, Dong XL , et al. High CD204 + tumor-infiltrating macrophage density predicts a poor prognosis in patients with urothelial cell carcinoma of the bladder [J]. Oncotarget, 2015,6(24):20204-20214.
[18] Kawachi A, Yoshida H, Kitano S , et al. Tumor-associated CD204 + M2 macrophages are unfavorable pro-gnostic indicators in uterine cervical adenocarcinoma [J]. Cancer Sci, 2018,109(3):863-870.
[19] Wang YP, Chen C, Hua QQ , et al. Downregulation of leucine‑rich‑α‑2‑glycoprotein 1 expression is associated with the tumorigenesis of head and neck squamous cell carcinoma[J]. Oncol Rep, 2017,37(3):1503-1510.
[20] Chen R, Luo FK, Wang YL , et al. LBP and CD14 polymorphisms correlate with increased colorectal carcinoma risk in Han Chinese[J]. World J Gastroenterol, 2011,17(18):2326-2331.
[21] Chang CM, Chia VM, Gunter MJ , et al. Innate immunity gene polymorphisms and the risk of colorectal neoplasia[J]. Carcinogenesis, 2013,34(11):2512-2520.
[22] Cai QY, Jiang JH, Jin RM , et al. The clinical significance of lipopolysaccharide binding protein in hepatocellular carcinoma[J]. Oncol Lett, 2020,19(1):159-166.
[23] Kubota K, Moriyama M, Furukawa S , et al. CD163 + CD204 + tumor-associated macrophages contribute to T cell regulation via interleukin-10 and PD-L1 production in oral squamous cell carcinoma [J]. Sci Rep, 2017,7(1):1755.
[24] Kurago ZB, Lam-ubol A, Stetsenko A, et al. Lipopolysaccharide-squamous cell carcinoma-monocyte interactions induce cancer-supporting factors leading to rapid STAT3 activation[J].Head Neck Pathol, 2008,2(1):1-12.
[25] Utispan K, Pugdee K, Koontongkaew S . Porphyromonas gingivalis lipopolysaccharide-induced ma-crophages modulate proliferation and invasion of head and neck cancer cell lines[J]. Biomed Pharmacother, 2018,101:988-995.
[1] 周金阔,张晋弘,史晓晶,刘广顺,姜磊,刘倩峰. 长链非编码RNA小核仁RNA宿主基因22调控微小RNA-27b-3p对口腔鳞状细胞癌细胞增殖、侵袭和迁移的影响[J]. 国际口腔医学杂志, 2024, 51(1): 52-59.
[2] 李立恒,王蕊,王晓明,张智轶,张璇,安峰,王芹,张凡. 环状RNA hsa_circ_0085576调控微小RNA-498/B细胞特异性莫洛尼鼠白血病病毒整合位点1轴对口腔鳞状细胞癌细胞迁移和侵袭的影响[J]. 国际口腔医学杂志, 2024, 51(1): 60-67.
[3] 吴佳敏,夏斌,杨禾丰,许彪. 癌相关成纤维细胞在口腔鳞状细胞癌微环境中作用的研究进展[J]. 国际口腔医学杂志, 2023, 50(6): 711-717.
[4] 柳江龙, 买买提吐逊·吐尔地. 超声造影在口腔鳞状细胞癌颈部转移性淋巴结诊断中的研究进展[J]. 国际口腔医学杂志, 2023, 50(5): 514-520.
[5] 盛南宁,王珏,南欣荣. 性别决定基因盒9在口腔鳞状细胞癌作用机制和治疗中的研究进展[J]. 国际口腔医学杂志, 2023, 50(3): 314-320.
[6] 李潭,梁新华. 盘状蛋白结构域受体1在调控恶性肿瘤进展和治疗中的作用[J]. 国际口腔医学杂志, 2023, 50(2): 230-236.
[7] 赵卓平,辛鹏飞,高阳,张彩凤,张宽收,刘青梅. 光热治疗在口腔鳞状细胞癌治疗中的研究进展[J]. 国际口腔医学杂志, 2022, 49(4): 462-470.
[8] 江涵,神应强,陈谦明. 毒蕈碱受体通过Yes相关蛋白信号对口腔鳞状细胞癌生物学行为的实验研究[J]. 国际口腔医学杂志, 2022, 49(2): 138-143.
[9] 蒋宇磊,夏斌,饶南荃,杨禾丰,许彪. 外泌体在口腔鳞状细胞癌恶性进展及诊疗应用的研究[J]. 国际口腔医学杂志, 2021, 48(6): 711-717.
[10] 甘建国,高攀,王晓毅. 循环肿瘤细胞与口腔鳞状细胞癌相关性的研究进展[J]. 国际口腔医学杂志, 2021, 48(2): 205-212.
[11] 何宇晴,但红霞,陈谦明. 光动力疗法在口腔黏膜癌变防治中的应用[J]. 国际口腔医学杂志, 2020, 47(6): 669-676.
[12] 郝福,宁毅,孙睿,郑晓旭. 口腔鳞状细胞癌中转化因子2β的表达及潜在的临床意义[J]. 国际口腔医学杂志, 2020, 47(2): 159-165.
[13] 薛伶俐,李雅冬. 经首次根治性手术治疗口腔鳞状细胞癌患者的生存相关影响因素分析[J]. 国际口腔医学杂志, 2020, 47(2): 166-174.
[14] 董云梅,陶艳,周瑜. 口腔黏膜癌变过程中血清生化标志物的研究进展[J]. 国际口腔医学杂志, 2020, 47(1): 43-50.
[15] 陈宏丽,杨敬,尹刚,李皓缘,乔燕. 锌指蛋白32在口腔鳞状细胞癌中的表达意义及对口腔鳞状细胞癌干细胞的影响[J]. 国际口腔医学杂志, 2019, 46(6): 631-639.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 王昆润. 二甲亚砜和双氯芬酸并用治疗根尖周炎[J]. 国际口腔医学杂志, 1999, 26(06): .
[2] 汤庆奋,王学侠. 17β-雌二醇对人类阴道和口腔颊粘膜的渗透性[J]. 国际口腔医学杂志, 1999, 26(06): .
[3] 潘劲松. 颈总动脉指压和颈内动脉球囊阻断试验在大脑血液动力学中的不同影响[J]. 国际口腔医学杂志, 1999, 26(05): .
[4] 王昆润. 后牙冠根斜形牙折的治疗[J]. 国际口腔医学杂志, 1999, 26(05): .
[5] 杨锦波. 嵌合体防龋疫苗的研究进展[J]. 国际口腔医学杂志, 1999, 26(05): .
[6] 王昆润. 下颔骨成形术用网状钛板固定植骨块[J]. 国际口腔医学杂志, 1999, 26(04): .
[7] 汪月月,郭莉莉. 口腔机能与老化—痴呆危险因素流行病学研究[J]. 国际口腔医学杂志, 1999, 26(04): .
[8] 丁刚. 应用硬组织代用品种植体行丰颏术[J]. 国际口腔医学杂志, 1999, 26(04): .
[9] 田磊. 局部应用脂多糖后结合上皮反应性增生的变化[J]. 国际口腔医学杂志, 1999, 26(04): .
[10] 戴青. 口腔念珠菌病的新分类[J]. 国际口腔医学杂志, 1999, 26(04): .